# US 10,307,424 B2 · Drug with hepatoprotective activity > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,307,424 B2 - Document ID: US10307424B2 - Status: Granted - Kind: B2 - Application number: 15/562,294 - Filed: 2016-03-23 - Published: 2018-11-29 - Granted: 2019-06-04 - Earliest claimed: 2015-03-27 - Assignees: Georgy Viktorovich Tets; Viktor Veniaminovich Tets - Applicants: Viktor Veniaminovich Tets; Georgy Viktorovich Tets - Inventors: Viktor Veniaminovich Tets; Georgy Viktorovich Tets; Konstantin Andreevich Krasnov - Web page: https://patentgrep.com/patent/US10307424B2 ## CPC - A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics - C07D 239/545: with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) ## Abstract The invention relates to pharmacology and can be used for treating liver diseases of various etiologies, inter alia, in combination with other preparations. Claimed is a drug with hepatoprotective activity comprised of 3-(4-bromophenyl)-6,6-dihydroxy-5-hydroxyiminohexahydro-2,4-pyrimidinedione and salts thereof of general formula (I), where X is selected from the group: H, Na, K, or from the group of hydroxyalkylammonia derivatives of general formula (II), where R1, R2 are selected from the group: H, CH3, CH2CH3, CH2CH2OH; R3 is selected from the group: H, CH2OH; and n=1, 2; the drug can be prepared in the form of tablets or capsules for enteral administration; or in the form of a liquid or lyophilized substance for parenteral administration; or in the form of rectal suppositories; or in the form of capsules or tablets, or sweets for sucking; and may additionally contain the hepatoprotector Heptral; or the hepatoprotector Essentiale; or the hepatoprotector ursodeoxycholic acid. This increases the effectiveness of a drug with hepatoprotective activity. ## Claims ### Claim 1 A compound 3-(4-bromophenyl)-6,6-dihydroxy-5-hydroxyiminohexahydro-2,4-pyrimidinedione and salts thereof, having a structure according to general formula: wherein X is selected from the group consisting of H, Na, K, and a hydroxyalkylammonium derivative of general formula: wherein R1 and R2 are selected from H, CH3, CH2CH3, and CH2CH2OH; R3 is selected from H, CH2OH, and n=1 or 2. ### Claim 2 (depends on 1) The compound of claim 1, wherein the compound is substantially isolated. ### Claim 3 (depends on 1) The compound of claim 1, wherein X is H and the compound is produced by reacting an aqueous solution of 1-(4-bromophenyl)violuric acid with sulfuric acid, cooling the resulting solution, and isolating the resultant solid residue. ### Claim 4 (depends on 1) The compound of claim 1, wherein X is H. ### Claim 5 (depends on 1) The compound of claim 1, wherein X is Na. ### Claim 6 (depends on 1) The compound of claim 1, wherein X is K. ### Claim 7 (depends on 1) The compound of claim 1, wherein X is R1 and R2 are each H, R3 is CH2OH, and n=1. ### Claim 8 (depends on 1) A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or excipient. ### Claim 9 (depends on 8) The pharmaceutical composition of claim 8, further comprising an additional agent selected from Heptral, Essentiale, and ursodeoxycholic acid. ### Claim 10 (depends on 1) A pharmaceutical dosage form comprising the compound of claim 1, wherein the dosage form is selected from a tablet, a capsule, a liquid, a lyophilized substrate, a suppository, a cachet, and a sweet. ### Claim 11 (depends on 1) A pharmaceutical dosage form comprising the compound of claim 1, wherein the dosage form is for enteral administration. ### Claim 12 (depends on 1) A pharmaceutical dosage form comprising the compound of claim 1, wherein the dosage form is for parenteral administration. ### Claim 13 (depends on 8) A method of treating a liver disease in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 8. ### Claim 14 (depends on 13) The method of claim 13, wherein the liver disease is selected from hepatitis, intrahepatic cholestasis, hepatic encephalopathy, toxic liver damage, alcoholic liver disease, fatty hepatosis, and liver cirrhosis. ### Claim 15 (depends on 14) The method of claim 14, wherein the hepatitis is chronic hepatitis, toxic hepatitis, or alcoholic hepatitis. ### Claim 16 (depends on 13) The method of claim 13, wherein the pharmaceutical composition is administered enterally. ### Claim 17 (depends on 13) The method of claim 13, wherein the pharmaceutical composition is administered parenterally. ### Claim 18 (depends on 13) The method of claim 13, wherein the method further comprises administering an additional agent selected from Heptral, Essentiale, and ursodeoxycholic acid. ### Claim 19 (depends on 1) A method of treating a liver disease in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of the compound of claim 1. ### Claim 20 (depends on 19) The method of claim 19, wherein the liver disease is selected from hepatitis, intrahepatic cholestasis, hepatic encephalopathy, toxic liver damage, alcoholic liver disease, fatty hepatosis, and liver cirrhosis. ### Claim 21 (depends on 20) The method of claim 20, wherein the hepatitis is chronic hepatitis, toxic hepatitis, or alcoholic hepatitis. ### Claim 22 (depends on 19) The method of claim 19, wherein the compound is administered enterally. ### Claim 23 (depends on 19) The method of claim 19, wherein the compound is administered parenterally. ### Claim 24 (depends on 19) The method of claim 19, wherein the method further comprises administering an additional agent selected from Heptral, Essentiale, and ursodeoxycholic acid.